Company Encyclopedia
View More
name
CollPlant Biotech
CLGN.US
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company’s products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product.
1.902 T
CLGN.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking159/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-92.74%E
    • Profit Margin-491.31%E
    • Gross Margin-249.35%E
  • Growth ScoreB
    • Revenue YoY280.77%A
    • Net Profit YoY30.20%B
    • Total Assets YoY-37.22%E
    • Net Assets YoY-45.00%E
  • Cash ScoreB
    • Cash Flow Margin-20.35%D
    • OCF YoY280.77%A
  • Operating ScoreE
    • Turnover0.14E
  • Debt ScoreB
    • Gearing Ratio33.96%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CollPlant Biotechnologies Ltd. Announces Date for Annual and Extraordinary General Meeting of Shareholders

    CollPlant Biotechnologies Ltd. will hold its Annual and Extraordinary General Meeting of Shareholders on December 31, 2025. Shareholders will vote on proposals recommended by the Board of Directors. Specific resolutions are not detailed. The news was generated by Public Technologies using AI and is based on information published by CollPlant via EDGAR on November 26, 2025.

    Reuters·
    US
    CLGN
    -4.74%
    Reuters·
    US
    CLGN
    -4.74%

    CollPlant Biotechnologies shares are trading lower after the company reported worse-than-expected Q3 financial results.

    benzinga_article·
    US
    CLGN
    -4.74%
    benzinga_article·
    US
    CLGN
    -4.74%

    CollPlant Biotechnologies Expands North American Operations and Reports Q3 2025 Results

    CollPlant Biotechnologies reported its Q3 2025 financial results, highlighting strategic initiatives like expanding rhCollagen and BioInk sales in North America through a new logistics partnership. The company is collaborating with Mayo Clinic on a bioprinted skin model and expanding its tendon-repair product distribution. Despite these advancements, the stock is rated as a Hold with a $2.00 price target due to poor financial performance and a bearish technical trend, indicating a high-risk investment.

    Tip Ranks·
    US
    CLGN
    -4.74%
    Tip Ranks·
    US
    CLGN
    -4.74%

    CollPlant Biotechnologies' Q3 revenue rises on rhCollagen sales, cuts workforce

    CollPlant Biotechnologies reported a significant increase in Q3 2025 revenue driven by rhCollagen sales and a $2 million milestone payment from AbbVie. The company announced a 25% workforce reduction to extend its cash runway and plans to expand its North American distribution through a new U.S. logistics partnership. Analysts rate the stock as a "buy," with a median 12-month price target of $11.50, significantly above its current price.

    Reuters·
    US
    CLGN
    -4.74%
    Reuters·
    US
    CLGN
    -4.74%

    Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million

    CollPlant Biotechnologies Ltd. reported a 35% reduction in net loss for the nine months ended September 30, 2025, totaling USD 8.3 million. Q3 2025 revenues were USD 1.4 million with a net loss of USD 3.5 million. The company is focusing on expanding rhCollagen and BioInk sales in North America and implementing cost reduction initiatives.

    Reuters·
    US
    CLGN
    -4.74%
    Reuters·
    US
    CLGN
    -4.74%
    © 2025 Longbridge｜Disclaimer